SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

2/9/24 10:05:23 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VRTX alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 VERTEX PHARMACEUTICALS INC COMMON STOCK Cusip #92532F100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #92532F100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 12,217,663 Item 6: 0 Item 7: 12,981,286 Item 8: 0 Item 9: 12,981,286 Item 11: 5.037% Item 12: HC Cusip #92532F100 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 12,981,286 Item 8: 0 Item 9: 12,981,286 Item 11: 5.037% Item 12: IN Item 1(a). Name of Issuer: VERTEX PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 50 Northern Avenue Boston, MA 02210 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 92532F100 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 12,981,286 (b) Percent of Class: 5.037% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 12,981,286 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of VERTEX PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of VERTEX PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Crosby Advisors LLC N/A FIAM LLC IA Fidelity Diversifying Solutions LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of VERTEX PHARMACEUTICALS INC at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $VRTX alert in real time by email

Recent Analyst Ratings for

$VRTX

Date	Price Target	Rating	Analyst
11/14/2024	$575.00	Buy	Citigroup
10/16/2024		Sector Perform	Scotiabank
10/10/2024		Mkt Perform	Raymond James
8/5/2024	$472.00 → $509.00	Overweight → Equal Weight	Barclays
6/27/2024	$545.00	Buy	Redburn Atlantic
4/11/2024	$438.00	In-line → Outperform	Evercore ISI
2/15/2024	$515.00	Outperform	Wolfe Research
2/6/2024	$436.00 → $438.00	Outperform → In-line	Evercore ISI

More analyst ratings

SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

Chat with this insight

Recent Analyst Ratings for $VRTX

$VRTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, Chief Scientific Officer Altshuler David sold $7,178 worth of shares (15 units at $478.56), decreasing direct ownership by 0.06% to 25,813 units (SEC Form 4)

EVP & Chief Financial Officer Wagner Charles F Jr sold $1,554,810 worth of shares (3,000 units at $518.27), decreasing direct ownership by 6% to 44,137 units (SEC Form 4)

CEO & President Kewalramani Reshma sold $7,826,970 worth of shares (15,198 units at $515.00), decreasing direct ownership by 17% to 75,772 units (SEC Form 4)

$VRTX Press Releases

Fastest customizable press release news feed in the world

Vertex Reports Third Quarter 2024 Financial Results

Vertex to Participate in Upcoming November Investor Conferences

Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress

$VRTX Financials

Live finance-specific insights

Vertex Reports Third Quarter 2024 Financial Results

Vertex to Announce Third Quarter 2024 Financial Results on November 4th

Vertex Reports Second Quarter 2024 Financial Results

$VRTX Leadership Updates

Live Leadership Updates

Vertex Appoints Nancy Thornberry to its Board of Directors

Vertex Appoints Michel Lagarde to its Board of Directors

Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

$VRTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citigroup initiated coverage on Vertex Pharma with a new price target

Scotiabank initiated coverage on Vertex Pharma

Raymond James resumed coverage on Vertex Pharma

$VRTX SEC Filings

SEC Form 10-Q filed by Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

$VRTX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

$VRTX Market Insights

Live Market Insights

TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $500

Here's How Much $100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today

Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $480

$VRTX Large Ownership Changes

This live feed shows all institutional transactions in real time.